Biontech SE (BNTX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 9.14 is considered Overvalued compared with the five-year average of -5.44. The fair price of Biontech SE (BNTX) is between 50.15 to 102.11 according to relative valuation method. Compared to the current price of 107.48 USD , Biontech SE By Overvalued By 5.26%.

Relative Value

Fair Zone

50.15-102.11

Current Price：107.48

5.26%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Biontech SE (BNTX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Biontech SE (BNTX) has a current Price-to-Book (P/B) ratio of 1.07. Compared to its 3-year average P/B ratio of 1.17, the current P/B ratio is approximately -8.02% higher. Relative to its 5-year average P/B ratio of 3.22, the current P/B ratio is about -66.69% higher. Biontech SE (BNTX) has a Forward Free Cash Flow (FCF) yield of approximately -2.50%. Compared to its 3-year average FCF yield of 15.22%, the current FCF yield is approximately -116.40% lower. Relative to its 5-year average FCF yield of 14.37%, the current FCF yield is about -117.37% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BNTX competitors is 6.73, providing a benchmark for relative valuation. Biontech SE Corp (BNTX.O) exhibits a P/S ratio of 9.14, which is 35.87% above the industry average. Given its robust revenue growth of 22.02%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BNTX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BNTX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BNTX currently overvalued or undervalued?

What is Biontech SE (BNTX) fair value?

BNTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Biontech SE (BNTX) is between 50.15 to 102.11 according to relative valuation method.

How does BNTX's valuation metrics compare to the industry average?

The average P/S ratio for BNTX's competitors is 6.73, providing a benchmark for relative valuation. Biontech SE Corp (BNTX) exhibits a P/S ratio of 9.14, which is 35.87% above the industry average. Given its robust revenue growth of 22.02%, this premium appears sustainable.

What is the current P/B ratio for Biontech SE (BNTX) as of Mar 03 2026?

As of Mar 03 2026, Biontech SE (BNTX) has a P/B ratio of 1.07. This indicates that the market values BNTX at 1.07 times its book value.

What is the current FCF Yield for Biontech SE (BNTX) as of Mar 03 2026?

As of Mar 03 2026, Biontech SE (BNTX) has a FCF Yield of -2.50%. This means that for every dollar of Biontech SE's market capitalization, the company generates -2.50 cents in free cash flow.

What is the current Forward P/E ratio for Biontech SE (BNTX) as of Mar 03 2026?

As of Mar 03 2026, Biontech SE (BNTX) has a Forward P/E ratio of -17.54. This means the market is willing to pay $-17.54 for every dollar of Biontech SE's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Biontech SE (BNTX) as of Mar 03 2026?

As of Mar 03 2026, Biontech SE (BNTX) has a Forward P/S ratio of 9.14. This means the market is valuing BNTX at $9.14 for every dollar of expected revenue over the next 12 months.

BNTX Valuation